Bhatt Shailendra, Sharma Jai Bharti, Kamboj Ruchi, Kumar Manish, Saini Vipin, Mandge Shailendra
Maharishi Markandeshwar College of Pharmacy, Department of Pharmaceutics, Haryana, India.
Maharishi Markandeshwar University, Department of Pharmaceutics, Solan, India.
Turk J Pharm Sci. 2021 Feb 25;18(1):61-67. doi: 10.4274/tjps.galenos.2019.32656.
This work aims to develop nanostructured lipid carriers (NLCs) to improve the oral bioavailability of febuxostat (FEB).
High shear homogenization, a well-known technique, followed by bath sonication with slight modifications was used to prepare FEB-loaded NLCs using oleic acid as liquid lipid and stearic acid as solid lipid. A total of 3² full factorial design was utilized to examine the effect of 2 independent variables, namely, X1 (liquid to solid lipid ratio) and X2 (surfactant concentration) on the Y1 (particle size) and Y2 (% entrapment efficiency) of the drug. The prepared NLCs were evaluated for particle size, polydispersity index, zeta potential, and (%) entrapment efficiency.
The drug's highest solubility was found in the stearic (solid lipid) and oleic acid (liquid lipid), which were further chosen for NLC preparation. Result of the present study showed an increase in entrapment efficiency and a decrease in particle size with the increase in liquid lipid to solid lipid ratio. With increased surfactant concentration, a small particle size is observed. The optimized formulation's particle size and (%) entrapment efficiency was found to be 99 nm and 80%, respectively. The formulations' zeta potential and polydispersity index were found within the range. Compared to plain drug suspension, the optimized formulation showed higher drug release, which may be due to the presence of the higher amount of liquid lipid. The particles shown in the transmission electron microscopy were round in shape and have smooth surface. Stability studies showed that the NLC formulation can be stored for a longer time period under room condition.
FEB-loaded NLC were successfully prepared using full 3² factorial design, and can be further used for oral delivery of FEB for gout treatment.
本研究旨在开发纳米结构脂质载体(NLCs)以提高非布司他(FEB)的口服生物利用度。
采用高剪切均质化这一知名技术,并对其进行轻微修改后进行浴式超声处理,以油酸为液态脂质、硬脂酸为固态脂质制备载有FEB的NLCs。总共采用3²全因子设计来研究2个自变量,即X1(液态脂质与固态脂质的比例)和X2(表面活性剂浓度)对药物的Y1(粒径)和Y2(包封率)的影响。对制备的NLCs进行粒径、多分散指数、zeta电位和(%)包封率的评估。
发现该药物在硬脂酸(固态脂质)和油酸(液态脂质)中的溶解度最高,因此进一步选用它们来制备NLCs。本研究结果表明,随着液态脂质与固态脂质比例的增加,包封率提高,粒径减小。随着表面活性剂浓度的增加,观察到粒径变小。优化后的制剂的粒径和(%)包封率分别为99 nm和80%。制剂的zeta电位和多分散指数在该范围内。与普通药物混悬液相比,优化后的制剂显示出更高的药物释放,这可能是由于存在较高量的液态脂质。透射电子显微镜显示的颗粒呈圆形且表面光滑。稳定性研究表明,NLC制剂在室温条件下可储存更长时间。
采用全3²因子设计成功制备了载有FEB的NLCs,可进一步用于口服递送FEB以治疗痛风。